Anebulo reports Q4 net loss $0.10/share; cash $14.5M; positive Phase 2 data for ANEB-001

Anebulo Pharmaceuticals, Inc.

Q4 fiscal 2022 net loss of $2.3M ($0.10 per share), vs $29.1M ($1.59) in prior year quarter.
Operating expenses Q4 $2.3M; fiscal year $6.8M; cash burn Q4 $2.0M; cash at June 30 $14.5M.
Positive Phase 2 Part A topline: ANEB-001 significantly reduced VAS feeling high (p<0.0001) and improved alertness (p<0.01).
Plan to initiate Part B evaluating lower doses by end of Q3 2022; IND submission for U.S. trials by end of 2022.
Inaugural R&D Day scheduled for September 26, 2022 in New York City; Part B data to be presented.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.